Johnson & Johnson (J&J), one of the major makers of Covid-19 vaccines, had net income of $5.15 billion in the first quarter of 2022, 17% lower than the gain of $6.2 billion. calculated in the same period last year, according to balance published this Tuesday (19).
With adjustments, J&J’s earnings per share between January and March were $2.67, above the forecast of analysts polled by FactSet of $2.58.
The US pharmaceutical group’s revenue grew 5% year-on-year in the first quarter, to $23.4 billion, but was slightly below the FactSet consensus of $23.62 billion.
J&J also lowered its forecasts for this year’s adjusted earnings per share to a range of $10.15 to $10.35 and for revenue to a range of $94.8 billion to $95. .8 billion.
Still on the balance sheet, J&J suspended forecasts for Covid-19 vaccine sales, citing a global surplus and demand uncertainties.
After the release of the results, the J&J share was down 1.3% in pre-market business in New York, at 8:00 am (Brasilia time).
Source: CNN Brasil
I am Sophia william, author of World Stock Market. I have a degree in journalism from the University of Missouri and I have worked as a reporter for several news websites. I have a passion for writing and informing people about the latest news and events happening in the world. I strive to be accurate and unbiased in my reporting, and I hope to provide readers with valuable information that they can use to make informed decisions.
